Subcutaneous Versus Intravenous Amivantamab, Both in Combination with Lazertinib, in Refractory EGFR-mutated NSCLC: Primary Results from the Phase 3 PALOMA-3 Study Natasha B. Leighl , Hiroaki Akamatsu , Sun Min Lim , Ying Cheng , Anna R. Minchom , Melina E. Marmarelis , Rachel E. Sanborn , James Chih-Hsin Yang , Baogang Liu , Thomas John , Bartomeu Massutí , Alexander I. Spira , Se-Hoon Lee , Jialei Wang , Juan Li , Caigang Liu , Silvia Novello , Masashi Kondo , Motohiro Tamiya , Ernesto Korbenfeld , Mor Moskovitz , Ji-Youn Han , Mariam Alexander , Rohit Joshi , Enriqueta Felip , Pei Jye Voon , Pongwut Danchaivijitr , Ping-Chih Hsu , Felipe José Silva Melo Cruz , Thomas Wehler , Laurent Greillier , Encarnação Teixeira , Danny Nguyen , Joshua K. Sabari , Angel Qin , Dariusz Kowalski , Mehmet Ali Nahit Şendur , John Xie , Debopriya Ghosh , Ali Alhadab , Nahor Haddish-Berhane , Pamela L. Clemens , Patricia Lorenzini , Remy B. Verheijen , Mohamed Gamil , Joshua M. Bauml , Mahadi Baig , Antonio Passaro Journal of Clinical Oncology（2024）
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
